AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,946.00p
   
  • Change Today:
      32.00p
  • 52 Week High: 12,294.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.22m
  • Volume: 1,201,194
  • Market Cap: £169,687m
  • RiskGrade: 123

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 2.1% 0.0%
Div Cover 1.3 2.6
Op Mrgn 17.9% 30.5%
ROCE 60.1%  
Latest F'cast
P/E 35.3 17.2
PEG 0.4 0.2
Pr/Revenue 4.6 3.4
Pr/Book 5.4  
Latest F'cast
Revenue 3.3% -10.6%
PBT 175.8% 81.2%
EPS 81.1% 112.3%
DPS n/a -30.4%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 24,384.00 1,548.00 103.00¢ 91.4 n/a -39% 280.00¢ 3.0%
31-Dec-20 26,617.00 3,916.00 244.00¢ 37.1 0.3 +137% 280.00¢ 3.1%
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,342.0 n/a -97% 287.00¢ 2.7%
31-Dec-22 44,351.00 2,501.00 212.00¢ 65.5 0.0 +2,550% 290.00¢ 2.1%
31-Dec-23 45,811.00 6,899.00 384.00¢ 34.1 0.4 +81% 290.00¢ 2.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-24 50,655.05 15,467.38 654.40p 16.7 0.1 +112% 249.73p 0.0%
31-Dec-25 54,330.25 17,521.10 743.27p 14.7 1.1 +14% 262.06p 0.0%
31-Dec-26 56,957.48 19,296.43 805.13p 13.6 1.6 +8% 273.56p 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Result of AGM 11-Apr-2024 17:30 RNS
AstraZeneca increases 2024 dividend by 7% 11-Apr-2024 07:00 RNS
Enhertu approved in US for HER2+ solid tumours 08-Apr-2024 07:00 RNS

AstraZeneca ShareCast News

London close: Stocks finish lower as ECB stands ... 11-Apr-2024 ShareCast
AstraZeneca to hike 2024 dividend by 7% 11-Apr-2024 ShareCast
AstraZeneca's Enhurtu cancer gets US green light... 08-Apr-2024 ShareCast

AstraZeneca Top Newspaper Links

Proxy advisory groups under fire after AstraZene... 15-Apr-2024 Times
AstraZeneca boss is ‘massively underpaid’ on £17m 10-Apr-2024 Times
Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,946.00p
Change Today 32.00p
% Change 0.29 %
52 Week High 12,294.00
52 Week Low 9,501.00
Volume 1,201,194
Shares Issued 1,550.22m
Market Cap £169,687m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
91.02% below the market average91.02% below the market average91.02% below the market average91.02% below the market average91.02% below the market average
92.45% below the sector average92.45% below the sector average92.45% below the sector average92.45% below the sector average92.45% below the sector average
Price Trend
24.58% above the market average24.58% above the market average24.58% above the market average24.58% above the market average24.58% above the market average
78.95% above the sector average78.95% above the sector average78.95% above the sector average78.95% above the sector average78.95% above the sector average
Income
86.95% below the market average86.95% below the market average86.95% below the market average86.95% below the market average86.95% below the market average
75% below the sector average75% below the sector average75% below the sector average75% below the sector average75% below the sector average
Growth
81.42% above the market average81.42% above the market average81.42% above the market average81.42% above the market average81.42% above the market average
94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average

What The Brokers Say

Strong Buy 8
Buy 12
Neutral 6
Sell 0
Strong Sell 2
Total 28
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 19-Apr-2024

Time Volume / Share Price
17:46 17,769 @ 10,775.45p
17:08 1,509 @ 10,821.57p
16:37 18 @ 10,946.00p
16:35 550 @ 10,946.00p
16:35 600 @ 10,946.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page